Related Experiment Videos
Cardioselective beta-blockers for chronic obstructive pulmonary disease
S Salpeter1, T Ormiston, E Salpeter
1Stanford University, and Santa Clara Valley Medical Center, Medicine, 2400 Moorpark Ave, Suite 118, San Jose, CA 95128, USA. shelley.salpeter@hhs.co.santa-clara.ca.us
The Cochrane Database of Systematic Reviews
|October 20, 2005
Summary
Cardioselective beta-blockers do not worsen respiratory function in patients with chronic obstructive pulmonary disease (COPD). These medications, beneficial for heart conditions, can be safely used in COPD patients without adverse effects.
Area of Science:
- Pulmonology
- Cardiology
- Pharmacology
Background:
- Beta-blocker therapy offers significant mortality benefits for patients with hypertension, heart failure, and coronary artery disease.
- Traditionally, beta-blockers were contraindicated in patients diagnosed with chronic obstructive pulmonary disease (COPD) due to concerns about respiratory function.
- This contraindication has led to the withholding of potentially beneficial cardiovascular treatments from COPD patients.
Purpose of the Study:
- To evaluate the impact of cardioselective beta-blockers on the respiratory function of individuals diagnosed with COPD.
- To determine if cardioselective beta-blockers cause adverse respiratory effects in COPD patients.
- To inform clinical practice regarding the use of cardioselective beta-blockers in patients with COPD.
Main Methods:
- A systematic review and meta-analysis of randomized, blinded, controlled trials were conducted.
- Searches included the Cochrane Airways Group Specialised Register, CENTRAL, MEDLINE, EMBASE, and CINAHL from 1966 to May 2005.
- Eleven studies (single-dose) and nine studies (longer duration) met the selection criteria, assessing forced expiratory volume in 1 second (FEV1) and respiratory symptoms.
Main Results:
- Cardioselective beta-blockers, administered as single doses or for longer durations (2 days to 12 weeks), did not significantly alter FEV1 or respiratory symptoms compared to placebo.
- These agents did not impede the bronchodilator response to beta2-agonists.
- Subgroup analyses confirmed no adverse effects in patients with severe chronic airways obstruction or reversible obstructive components.
Conclusions:
- The use of cardioselective beta-blockers in patients with COPD, as evidenced by the reviewed studies, does not result in adverse respiratory effects.
- Given their established cardiovascular benefits, cardioselective beta-blockers should not be routinely withheld from patients who also have COPD.
- This finding supports the re-evaluation of beta-blocker use in COPD patients with comorbid cardiovascular conditions.